Technical Analysis for RZLT - Rezolute Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 2.53% | |
| Bollinger Band Squeeze | Range Contraction | 2.53% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 2.53% | |
| Gapped Down | Weakness | 2.53% | |
| Lower Bollinger Band Touch | Weakness | 2.53% | |
| 20 DMA Resistance | Bearish | -2.17% | |
| 50 DMA Support | Bullish | -2.17% | |
| Bollinger Band Squeeze | Range Contraction | -2.17% | |
| Inside Day | Range Contraction | -2.17% | |
| 200 DMA Resistance | Bearish | -1.46% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | about 5 hours ago |
| Up 5% | about 8 hours ago |
| Up 1 ATR | about 8 hours ago |
| 200 DMA Resistance | about 8 hours ago |
| 50 DMA Resistance | about 8 hours ago |
Get this analysis on your stocks daily!
Rezolute Inc. Description
Rezolute, Inc., a clinical stage biopharmaceutical company, specializes in the development of drug therapies for the treatment of patients with metabolic and orphan diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema; and RZ602, a product candidate that is in preclinical trial for the treatment of hereditary angioedema. It also develops AB101, a human recombinant insulin, which is in Phase I clinical trial for the treatment of patients with type 1 and type 2 diabetes mellitus. Rezolute, Inc. has a development and license agreement with ActiveSite Pharmaceuticals, Inc. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Louisville, Colorado.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Organ Systems Diabetes Monoclonal Antibodies Stage Biopharmaceutical Recombinant Monoclonal Antibody Insulin Type 2 Diabetes Diabetic Retinopathy Diabetes Mellitus Drug Therapies Orphan Diseases Diabetic Macular Edema Orphan Disease Angioedema Complement Deficiency Hereditary Angioedema Macular Edema Statin Congenital Hyperinsulinism
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.59 |
| 52 Week Low | 1.34 |
| Average Volume | 34,088 |
| 200-Day Moving Average | 2.1320 |
| 50-Day Moving Average | 2.0442 |
| 20-Day Moving Average | 2.0828 |
| 10-Day Moving Average | 2.0685 |
| Average True Range | 0.1508 |
| RSI (14) | 44.44 |
| ADX | 11.5 |
| +DI | 18.2331 |
| -DI | 27.2430 |
| Chandelier Exit (Long, 3 ATRs) | 1.8476 |
| Chandelier Exit (Short, 3 ATRs) | 2.2424 |
| Upper Bollinger Bands | 2.1926 |
| Lower Bollinger Band | 1.9730 |
| Percent B (%b) | 0.03 |
| BandWidth | 10.5435 |
| MACD Line | -0.0105 |
| MACD Signal Line | 0.0008 |
| MACD Histogram | -0.0113 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.1000 | ||||
| Resistance 3 (R3) | 2.0967 | 2.0533 | 2.0800 | ||
| Resistance 2 (R2) | 2.0533 | 2.0228 | 2.0550 | 2.0733 | |
| Resistance 1 (R1) | 2.0167 | 2.0039 | 1.9950 | 2.0200 | 2.0667 |
| Pivot Point | 1.9733 | 1.9733 | 1.9625 | 1.9750 | 1.9733 |
| Support 1 (S1) | 1.9367 | 1.9428 | 1.9150 | 1.9400 | 1.8933 |
| Support 2 (S2) | 1.8933 | 1.9239 | 1.8950 | 1.8867 | |
| Support 3 (S3) | 1.8567 | 1.8933 | 1.8800 | ||
| Support 4 (S4) | 1.8600 |
